Clinical Trials Logo

Clinical Trial Summary

Zanubrutinib is a novel BTK inhibitor with proven activity in patients with various B-cell lymphomas addicted to the B-cell receptor signaling pathway.


Clinical Trial Description

Studies involving gene expression profiling and next generation sequencing have demonstrated that CNS lymphomas mostly are of the ABC-subtype and harbor mutations that reinforce BCR signaling. Ibrutinib, as the first BTK inhibitor, showed substantial activity in patients with R/R PCNSL and R/R SCNSL. Zanubrutinib is a novel BTK inhibitor with proven activity in patients with various B-cell lymphomas addicted to the B-cell receptor signaling pathway. In addition, pharmacological studies demonstrated the free drug exposure of zanubrutinib at 160 mg BID is roughly 10 times that of ibrutinib at 560 mg QD, and penetration into the CNS by zanubrutinib and ibrutinib is similar, suggesting the potential activity of zanubrutinib in the treatment of CNS lymphomas. However, the outcome of R/R PCNSL and R/R SCNSL patients treated with zanubrutinib monotherapy is still unclear. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05117814
Study type Interventional
Source Peking University People's Hospital
Contact Shenmiao Yang, Dr.
Phone 134399999810
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date September 2021
Completion date July 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04089449 - A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas Phase 1
Completed NCT01319591 - Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
Completed NCT01182415 - High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Phase 2
Recruiting NCT04841434 - A Phase I/II Study to Investigate the Use of VORAXAZEâ„¢ as Intended Intervention in Patients With CNSL Phase 1/Phase 2
Completed NCT01083342 - High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Phase 2
Active, not recruiting NCT00596154 - Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma Phase 2